VRD-based regimen

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China

Conditions

Multiple MyelomaPlasma Cell Leukemia

Phase 2

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Active, not recruitingNCT05850286

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2023-04-21End: 2028-04-01Target: 20Updated: 2026-06-03

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

RecruitingNCT05979363

Institute of Hematology & Blood Diseases Hospital, ChinaPlasma Cell Leukemia

Start: 2023-08-14End: 2028-07-01Target: 20Updated: 2025-08-03

Related Papers

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

Blood2025-11-03

CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.

Blood2025-11-03

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Blood2024-11-05